The Washington Post

Searching for an Alzheimer’s cure

More than five million people across the United States and some 30 million worldwide suffer from Alzheimer’s, a devastating disease that attacks the brain and leads to memory loss, the inability to perform daily tasks and functions, and eventually death.

Neil Buckholtz, the director of the Division of Neuroscience at the National Institute on Aging, has been the driving force behind an ambitious public-private partnership focused on finding the biological markers that show how Alzheimer’s progresses in the brain so that researchers can more quickly target the testing of new drugs to slow or stop the disease.

“Alzheimer’s disease is a major public health problem which will only get much worse if new ways to treat and prevent it are not found,” said Buckholtz. “It is critical for the federal government to facilitate the discovery, development and testing of new therapeutics to help people and their families who are desperately in need.”

This multi-million dollar project, started in 2004 and now in its second phase, has led to clinical trials at 57 sites in the United States and Canada, and involved participation of the National Institutes of Health, the Food and Drug Administration, universities, nonprofits and numerous pharmaceutical, diagnostic and biotechnology companies.

The initiative is unique not just because of its ambitious goals and the broad coalition of participants, but because of the requirement conceived by Buckholtz and colleagues that all of the data and findings be made available on a public database for use by scientists around the world. The database contains thousands of brain scan images, clinical and neuropsychological data, genetic information, and blood and cerebrospinal fluid analyses.

Neil Buckholtz (National Institute of Health)

Unlike most clinical trials, no one owns this data or can submit patent applications, but companies could eventually benefit from any drugs or imaging tests that are developed from use of the information. There are only a handful of medications approved for treatment of Alzheimer’s in the United States, but they do not stop the disease and have only marginal effects on the symptoms.

The project, formally known as the Alzheimer’s Disease Neuroimaging Initiative, has led to more than 170 scientific papers, helped lead to new insights into people at high risk of Alzheimer’s progression, and accelerated the testing of new medications. This collaboration also has been a model for biomarker studies in other diseases such as Parkinson’s and Down syndrome.

“This collaborative effort has deepened our understanding of this complex disorder. Numerous scientific laboratories are processing data, writing abstracts and papers, and reporting the results at meetings,” said Buckholtz. The results have been extremely positive and concrete and are being used extensively in academic and industry clinical trials.”

Dr. Richard Hodes, the director of the National Institute on Aging, said Buckholtz is an “outstanding scientist, administrator and public servant” who had a vision, worked with a group of diverse partners and has achieved remarkable success so far with additional progress on the horizon.

“Neil commands a great deal of respect,” said Hodes. “People have confidence and faith in his abilities and his desire to achieve a common goal, and they know he is even-handed and fair.

This project that he led is renowned for what it has accomplished.”

Buckholtz joined the National Institute of Mental Health in 1983 and later served as chief of the National Institute of Aging Dementias of Aging Branch from 1993-2012, where he managed the Alzheimer’s project. He briefly retired in 2012 before growing restless and coming back as director of the Division of Neuroscience, where he now oversees the project along broader responsibilities to reviewing grants and other research involving Alzheimer’s and dementia.

“I actually attempted to retire, but found that I am still drawn to the field and hope to continue to make contributions for as long as I can,” said Buckholtz. “I am motivated by what is going on in science and the chance we have to test and develop new drugs. It will be very gratifying if I can help in some way.”

This article was jointly prepared by the Partnership for Public Service, a group seeking to enhance the performance of the federal government, and Go to to nominate a federal employee for a Service to America Medal and to read about other federal workers who are making a difference.

The Freddie Gray case

Please provide a valid email address.

You’re all set!

Campaign 2016 Email Updates

Please provide a valid email address.

You’re all set!

Get Zika news by email

Please provide a valid email address.

You’re all set!
Show Comments
Republicans debated Saturday night. The South Carolina GOP primary and the Nevada Democratic caucuses are next on Feb. 20. Get caught up on the race.
The Post's Dan Balz says...
Rarely has the division between Trump and party elites been more apparent. Trump trashed one of the most revered families in Republican politics and made a bet that standing his ground is better than backing down. Drawing boos from the audience, Trump did not flinch. But whether he will be punished or rewarded by voters was the unanswerable question.
GOP candidates react to Justice Scalia's death
I don't know how he knows what I said on Univision because he doesn't speak Spanish.
Sen. Marco Rubio, attacking Sen. Ted Cruz in Saturday night's very heated GOP debate in South Carolina. Soon after, Cruz went on a tirade in Spanish.
The Fix asks The State's political reporter where the most important region of the state is.
The State's Andy Shain says he could talk about Charleston, which represents a little bit of everything the state has to offer from evangelicals to libertarians, and where Ted Cruz is raising more money than anywhere else. In a twist, Marco Rubio is drawing strong financial support from more socially conservative Upstate. That said, Donald Trump is bursting all the conventional wisdom in the state. So maybe the better answer to this question is, "Wherever Trump is."
Past South Carolina GOP primary winners
South Carolina polling averages
Donald Trump leads in the first state in the South to vote, where he faces rivals Ted Cruz and Marco Rubio.
South Carolina polling averages
The S.C. Democratic primary is Feb. 27. Clinton has a significant lead in the state, whose primary falls one week after the party's Nevada caucuses.
62% 33%
The complicated upcoming voting schedule
Feb. 20

Democrats caucus in Nevada; Republicans hold a primary in South Carolina.

Feb. 23

Republicans caucus in Nevada.

Feb. 27

Democrats hold a primary in South Carolina.

Upcoming debates
Feb 25: GOP debate

on CNN, in Houston, Texas

March 3: GOP debate

on Fox News, in Detroit, Mich.

March 6: Democratic debate

on CNN, in Flint, Mich.

Campaign 2016
Where the race stands
Most Read


Success! Check your inbox for details.

See all newsletters

Close video player
Now Playing

To keep reading, please enter your email address.

You’ll also receive from The Washington Post:
  • A free 6-week digital subscription
  • Our daily newsletter in your inbox

Please enter a valid email address

I have read and agree to the Terms of Service and Privacy Policy.

Please indicate agreement.

Thank you.

Check your inbox. We’ve sent an email explaining how to set up an account and activate your free digital subscription.